GTX Corp’s (GTXOD) GPS SmartSole in UK Trials th
Post# of 271
(Total Views: 293)
Posted On: 07/31/2018 4:58:53 PM
GTX Corp’s (GTXOD) GPS SmartSole in UK Trials through National Health Service
- GPS SmartSole in trials with the UK’s National Health Service (NHS)
- Could be issued across England through NHS
- GPS SmartSole set for distribution across the UK and Ireland
GTX Corp’s (OTC: GTXOD) GPS SmartSole, which is fitted with location-based technology, could soon become available in the UK through the country’s National Health Service (NHS), according to several British news reports (http://nnw.fm/8LswG). The wearable GPS device is undergoing tests in Dorset, England, to assess its ability to keep track of dementia patients (http://nnw.fm/28GQi). A number of organizations that work with those suffering from Alzheimer’s and dementia appear to be pushing for the product’s adoption, among them Tony Young, a national clinical director of NHS England, and Sally Copley, a senior official of the Alzheimer’s Society in the UK. Copley, who serves as the director of policy, campaigns and partnerships with the Alzheimer’s Society noted in a Barchester article (http://nnw.fm/MD1lL) that “the use of GPS tracking for people with dementia can provide reassurance and even save lives.” In light of the reports, GTX Corp and its distributor have begun to gear up. The company’s distributor in the UK is a well-established B2B health care and telehealth provider that sells and supports medical devices, along with the GPS SmartSole, across the UK and Ireland.
The number of people suffering from dementia in the UK is fast approaching one million. Their cognitive disability places them at great risk and causes relatives, guardians and caretakers concern. Dementia sufferers are notoriously prone to wandering off without telling anyone where they’re going. Moreover, in many instances, they don’t know themselves, as a result of which they can become disorientated, lost and likely to place themselves in peril. The numbers in the U.S. far exceeds those of the UK. Alzheimer’s disease afflicts an estimated 5.1 million Americans aged 65 years or older, a number that’s set to rise to 13.2 million by 2050 (http://nnw.fm/1b7UP), highlighting the possibility that the GPS SmartSole could enjoy the same widespread government support across other European countries and, ultimately, the U.S. health care market.
The GPS SmartSole is a sole insert that can be placed inside a shoe, making it invisible to the wearer. Settings on the device allow a specific area or ‘geo-fence’ to be designated as safe. Then, if the wearer steps outside that safe area, an alert will be sent to a connected digital device. The GPS SmartSole thus provides instant warning that something is amiss, prompting immediate remedial action. The system thus reduces risk to the wearer. Typically, seniors and other sufferers of cognitive disabilities are long lost before someone notices.
Alerts from the GPS SmartSole can be received on any internet-enabled device or smartphone, giving the location of the wearer so that he or she can be found quickly and significantly reducing the chances of harm. The device offers dementia patients increased independence and provides loved ones and caregivers with a reassuring peace of mind.
The distribution agreement, signed with Possum Ltd., will give GTX Corp access to a large market (http://nnw.fm/3yhyJ). The privately owned British company develops, manufactures, supplies, installs and supports electronic assistive technology products and systems to the National Health Service. It also distributes and supports a wide range of products to the telehealth and technology-enabled care and support markets. Operating since 1961, Possum is a former holder of one of the most prestigious business awards in the UK, the Queen’s Award for Enterprise in the Innovation category. With such a partner and with backing from NHS England, GTX Corp seems to be launching a sort of British invasion with its GPS SmartSole.
For more information, visit the company’s website at www.GTXCorp.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- GPS SmartSole in trials with the UK’s National Health Service (NHS)
- Could be issued across England through NHS
- GPS SmartSole set for distribution across the UK and Ireland
GTX Corp’s (OTC: GTXOD) GPS SmartSole, which is fitted with location-based technology, could soon become available in the UK through the country’s National Health Service (NHS), according to several British news reports (http://nnw.fm/8LswG). The wearable GPS device is undergoing tests in Dorset, England, to assess its ability to keep track of dementia patients (http://nnw.fm/28GQi). A number of organizations that work with those suffering from Alzheimer’s and dementia appear to be pushing for the product’s adoption, among them Tony Young, a national clinical director of NHS England, and Sally Copley, a senior official of the Alzheimer’s Society in the UK. Copley, who serves as the director of policy, campaigns and partnerships with the Alzheimer’s Society noted in a Barchester article (http://nnw.fm/MD1lL) that “the use of GPS tracking for people with dementia can provide reassurance and even save lives.” In light of the reports, GTX Corp and its distributor have begun to gear up. The company’s distributor in the UK is a well-established B2B health care and telehealth provider that sells and supports medical devices, along with the GPS SmartSole, across the UK and Ireland.
The number of people suffering from dementia in the UK is fast approaching one million. Their cognitive disability places them at great risk and causes relatives, guardians and caretakers concern. Dementia sufferers are notoriously prone to wandering off without telling anyone where they’re going. Moreover, in many instances, they don’t know themselves, as a result of which they can become disorientated, lost and likely to place themselves in peril. The numbers in the U.S. far exceeds those of the UK. Alzheimer’s disease afflicts an estimated 5.1 million Americans aged 65 years or older, a number that’s set to rise to 13.2 million by 2050 (http://nnw.fm/1b7UP), highlighting the possibility that the GPS SmartSole could enjoy the same widespread government support across other European countries and, ultimately, the U.S. health care market.
The GPS SmartSole is a sole insert that can be placed inside a shoe, making it invisible to the wearer. Settings on the device allow a specific area or ‘geo-fence’ to be designated as safe. Then, if the wearer steps outside that safe area, an alert will be sent to a connected digital device. The GPS SmartSole thus provides instant warning that something is amiss, prompting immediate remedial action. The system thus reduces risk to the wearer. Typically, seniors and other sufferers of cognitive disabilities are long lost before someone notices.
Alerts from the GPS SmartSole can be received on any internet-enabled device or smartphone, giving the location of the wearer so that he or she can be found quickly and significantly reducing the chances of harm. The device offers dementia patients increased independence and provides loved ones and caregivers with a reassuring peace of mind.
The distribution agreement, signed with Possum Ltd., will give GTX Corp access to a large market (http://nnw.fm/3yhyJ). The privately owned British company develops, manufactures, supplies, installs and supports electronic assistive technology products and systems to the National Health Service. It also distributes and supports a wide range of products to the telehealth and technology-enabled care and support markets. Operating since 1961, Possum is a former holder of one of the most prestigious business awards in the UK, the Queen’s Award for Enterprise in the Innovation category. With such a partner and with backing from NHS England, GTX Corp seems to be launching a sort of British invasion with its GPS SmartSole.
For more information, visit the company’s website at www.GTXCorp.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)